Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $462.4 million.

  • Protagonist Therapeutics' Short-term Investments rose 3696.8% to $462.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $462.4 million, marking a year-over-year increase of 3696.8%. This contributed to the annual value of $321.7 million for FY2024, which is 10768.24% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Short-term Investments of $462.4 million as of Q3 2025, which was up 3696.8% from $401.9 million recorded in Q2 2025.
  • Protagonist Therapeutics' Short-term Investments' 5-year high stood at $462.4 million during Q3 2025, with a 5-year trough of $225000.0 in Q2 2021.
  • For the 5-year period, Protagonist Therapeutics' Short-term Investments averaged around $207.1 million, with its median value being $190.5 million (2021).
  • As far as peak fluctuations go, Protagonist Therapeutics' Short-term Investments soared by 193790000.0% in 2021, and later plummeted by 5456.09% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Short-term Investments (Quarter) stood at $203.2 million in 2021, then tumbled by 45.08% to $111.6 million in 2022, then skyrocketed by 38.79% to $154.9 million in 2023, then soared by 107.68% to $321.7 million in 2024, then surged by 43.74% to $462.4 million in 2025.
  • Its last three reported values are $462.4 million in Q3 2025, $401.9 million for Q2 2025, and $434.7 million during Q1 2025.